The impact of cancer-associated thrombosis and treatment related bleedings on patients’ quality of life

This study aimed to capture UK societal utility values for health states associated with T2DM and treatment-related adverse events (AEs) to assess the burden of the disease and common AEs.

Quality of life of patients experiencing cancer-associated thrombosis

Objectives: Cancer patients are at high risk of venous thromboembolism (VTE), provoked by the cancer, chemotherapies or co-morbidities. The CATCH trial investigated the benefits of extended treatment with tinzaparin (LMWH) versus warfarin for the prevention of recurrent VTE events in cancer patients experiencing a VTE.